Monopar, NorthStar collaborate on potential COVID-19 treatment
Chicago-based Monopar Therapeutics is collaborating with a commercial producer of medical radioisotopes used for imaging to develop potential treatments for patients with severe COVID-19, according to a Tuesday statement.
Monopar Therapeutics, a biopharmaceutical company, will work with Wisconsin-based NorthStar Medical Radioisotopes on the therapy, which involves coupling an antibody to a radioisotope to create an agent they hope can reduce COVID-19-caused “runaway inflammation.”
The inflammation is thought to be largely responsible for severe organ damage that leads to poor outcomes and death in patients with the illness, according to a statement.
“This collaboration is a powerful combination of unique scientific and technical expertise to help combat severe COVID-19,” said Dr. Chandler Robinson, Monopar CEO.
Health News Illinois is removing the password on all stories related to the coronavirus. For the latest developments follow us on Twitter at @healthnewsil or check out our website. For complete healthcare coverage, sign up for a free trial to our daily email newsletter.